Cancer patients receiving chemotherapy are at risk of infection due to reduced white blood cell counts. Teva’s Tbo-filgrastim stimulates the bone marrow to produce white bloods cells. The US Food and Drug Administration has given the go-ahead for commercial production.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000780995&fid=1725